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Abstract: Hepatitis C virus (HCV) is a member of the family Flaviviridae, and the prin-
cipal cause of parenteral non A non B hepatitis. HCV is a single stranded, positive sense
RNAvirus whose genome contains a single open reading frame of about 10 kb in length
which encodes a polyprotein of about 3000 amino acids. HCV is responsible for majority of
the transfusion associated cases of hepatitis and a significant proportion of community-ac-
quired hepatitis which leads to a range of clinical manifestations from an apparent carrier
state to severe chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Cell-free
translation and cell culture transient expression studies revealed that HCV genome initially
transcribed as a polyprotein is processed by cellular and viral proteases to produce the
putative viral structural and nonstructural proteins. The preliminary map of the gene order
for HCV was established: 5' untranslated region (UTR)-core (C)-envelope 1 (E1)-E2-
nonstructural 2(NS2)-NS3-NS4A-NS4B-NS5A-NS5B-UTR3'. Nonstructural proteins, NS2,
NS3 and NS5, are believed to be a component of viral coded enzymes. Mutations in hyper-
variable region 1 (HVR1) of the E2 protein was considered to be a possible mechanism of
chronicity of HCV infection. HCV infection can be monitored either by serodiagnosis or by
genodiagnosis. Interferon seems to be considered as the sole drug for HCV treatment until
now.In the history of virology, HCV was the first example that was identified by molecular
cloning of its genome from infectious materials.
Key words: Hepatitis C virus, chronic hepatitis, genotypes, hepatocellular carcinoma, hyper-
variability, quasispecies, untranslated region
INTRODUCTION
Hepatitis caused by virus(es) other than hepatitis A virus (HAV), hepatitis B virus
(HBV), hepatitis delta virus (HDV) or other known hepatotropic viruses, such as cytomegalo-
virus, Epstein-Barr virus and human parvovirus (B19), have been referred to as non-A, non-B
(NANB) hepatitis. There are at least two types of NANB hepatitis reported, namely water-
borne and blood-borne NANB hepatitis (Alter et at., 1982; Sherlock, 1986). The causative
agent for water-borne hepatitis has recently been cloned, and it's genome was identified as a
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single stranded, positive sense polyadenylated RNA of about 7.6kb (Reyes et al, 1990). It is
nowdesignated as hepatitis E virus. Hepatitis E virus is endemic to the Indian subcontinent
and its clinical manifestations resemble to those by hepatitis A virus.
There are two types of aetiological agents for blood-borne NANB hepatitis as described
by cross-challenge and physicochemical studies (Yoshizawa et al, 1981, 1982; Bradley et al,
1983, 1985). One of them, the so-called tubule-forming agent, is chloroform sensitive and is
specifically associated with the formation of characteristic hepatocyte cytoplasomic altera-
tions in chimpanzees (Shimizu et al, 1979; Bradley et al, 1980). The genome of the tubule-
forming agent has recently been cloned and is composed of a single-stranded, positive sense
RNA of about 10000 bases (Choo et al., 1989). It is now designated as hepatitis C virus.
HCV was the first example in the history of virus which was identified by molecular cloning
of the viral genome. Another one, the so-called non-tubule forming agent, is not chloroform
sensitive and does not induce tubule formation when injected into chimpanzees. The
causative agent is still unidentified.
Here we report an overview of genomic structure of HCV and the role and function of
its different gene products in pathogenesis in liver diseases.
Importance as disease agent
HCV is responsible for the vast majority of transfusion-associated cases of hepatitis and
a significant proportion of community-acquired hepatitis worldwide which account for over
90% of all cases of non A non B hepatitis and 25% of sporadic acute viral hepatitis (Choo et
al, 1989; Kuo et al, 1989; Alter, 1989). By transient infection, HCV causes acute hepatitis,
certain proportion of which leads to chronic hepatitis followed by the development of liver cir-
rhosis, hepatocellular carcinoma and establishment of an asymtomatic carrier state which
maypersist for life (Hollinger, 1990). HCV infection is estimated to affect around 50 million
people around the world. Approximately 50% of the affected individuals gradually develop in-
to chronic infection of which about 20% eventually suffered from liver cirrhosis and
hepatocellular carcinoma (Mast and Alter, 1993). HCV infection is estimated to infect
100,000 to 300,000 new cases per year in the United States alone (Weiner et al, 1991).
Therefore, HCV is considered as one of the biggest healthcare problem throughout the
world,
Biological status of HCV
Extensive computer analysis of the nucleotide sequences and encoded polypeptides of
the first isolated CDNA clone obtained from a experimentally chimpanzee indicated that HCV
is unique in its genome structure which shows very little overall homology with known viral
sequences (Choo et al, 1989, 1991a). However, several lines of evidence indicate that HCV is
a akin of human flaviviruses and animal pestiviruses. Firstly, the length of the polyprotein en-
coded by the genome of these viruses is similar i.e. 3010, 3400 and 4000 respectively (Rice et
al, 1985; Choo et al, 1989; Collet et al, 1988a. b). Secondly, the organization of the genome
of these three viruses is almost similar i.e. 5' untranslated region (UTR) followed by struc-
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tural, nonstructural and 3' UTR (Choo et al, 1991a, b). Thirdly, all these viruses contain
several commonmotifs in the same region of the genome i.e. protease, NTP-binding and
helicase domains in the NS3 protein, and replicase domain in the NS5 protein (Bazan and
Fletterick, 1989; Gorbalenya et at., 1989; Miller and Purcell, 1990; Wengler and Wengler,
1993; Tamura et al., 1993; Suzich et at., 1993). Finally, the hydrophobicity profiles of the
polyproteins from these viruses are remarkably similar (Choo et al, 1991a; Takamizawa et
at., 1991). Considering all of these points HCV has been placed as the third genus in the fami-
ly Flaviviridae together with other two genus, flavivirm and pestivims (Choo et al., 1989;
Francki et al, 1991). Again HCV shows relatively closer relationship to pestiviruses than
flaviviruses in terms of the genetic organization of their envelope and NS5 proteins (Hijikata
et al, 1991a; Manabe et al, 1994). Flaviviruses contain a prM protein gene in between core
and envelope genes which is not present in pestiviruses and HCV.
Morphology of the HCV virion
Very little information has been accumulated on the morphological properties of the
HCV viral particles. Several attempts heve been initiated for the determination of the
buoyant density of the virion by gradient ultracentrifugation. The average buoyant density of
the virus particles was determined to be 1.08g/ml, which is similar to that of pestiviruses
(1.09-1.15 g/ml) and slightly lower than that of flaviviruses (1.20 g/ml) (Bradley et al, 1991;
Miyamoto et al, 1992, Hijikata et al, 1993c).
The particle size of HCV was determined as 30-38 nmby micro filtration (Yuasa et al,
1991). HCV particles were appeared as spherical with membranous envelope containing sur-
face projections which morphologically resemble flaviviruses. Abe et al. (1991) reported
37-40 nmparticles from the hepatocytes.
Genomestructure of HCV
Since the initial molecular cloning of this virus, the genome structure of several in-
dependent HCV isolates have heen elucidated and our knowledge of HCV molecular biology
is progressing rapidly. HCV is an enveloped, single-stranded, positive-sense RNA virus
whose genome is approximately 9,030 to 9,099 nucleotides in length and contains a highly
conserved 5' UTR followed by a long open reading frame encoding a polyprotein of 3,010 to
3,033 ammoacids (Choo et al, 1989; Kato et al, 1990; Takamizawa et al, 1991; Houghton et
al, 1991) which is processed by a combination of host and viral proteases (Hijikata et al,
1991a; Grakoui et al, 1993b). Due to lack of an efficient system for cell culture replication of
HCV, no definite study is possible to observe how the authentic polypeptides are produced in
HCV-infected cells. The map of the HCV polyprotein has been obtained by cell-free transla-
tion and cell culture transient expression studies (Hijikata et al, 1991a, 1993b; Grakoui et al,
1993b; Selby et al, 1993; Manabe et al, 1994). The gene map that has been obtained from
these studies is 5' UTR-C-E1-E2-NS2-NS3-NS4A-NS4B-NS5A-NS5B-3' UTR. C, El and E2
are viral putative structural genes wherease NS2 through NS5 are putative nonstructural
genes. A UTR of 324 to 341 nucleotides at the 5' terminus, and a variable length of UTR
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with either a poly(U) or a poly (A) tail at the 3' end, have been reported (Choo et al, 1989;
Han et al, 1991; Takamizawa et al, 1991).
Genomic Heterogeneity
Many HCV strains from different parts of the world have been entirely and partially se-
quenced and the data revealed that the nucleotide sequence between types (groups) as well
as various isolates of the same type vary in different regions of the HCV genome (Esumi and
Shikata, 1994). Some regions of the genome, especially 5' terminal UTR, are highly conserv-
ed, showing 93-99% homology among different isolates. The core regions of different
isolates exhibit identity of 81-96% in the nucleotide sequence and 90-98% in the amino
acid sequence, respectively. But some regions of the genome show very low homology, for in-
stance, envelope coding region (El and E2) and the NS2. These regions showed very low
nucleotide sequence homology between type II and III or IV, with a identity of 55-69% and
between type I and II, with a identity of 71-75%, NS3, NS4 and NS5 also showed con-
siderable variation both at nucleotide and putative amino acid sequences between different
types. Marked genetic variation was noted in the 3' UTR.
Proteolytic processing of the viral polyprotein
Due to lack of a laboratory experimental animal except chimpanzee, and an efficient
cell culture system, the study of the exact processing mechanism of the HCV polyprotein in
vitro has not been possible since the discovery of this virus. Several attempts have been
made to study the processing of the HCV polyprotein in vitro using cell-free translation and
cell culture transient expression systems (Hijikata et al, 1991a, 1993b; Harada et al., 1991;
Grakoui et al, 1993b; Selby et al, 1993; Manabe et al, 1994). These studies established that
HCV polyprotein is processed by cellular and viral encoded proteases to produce putative
structural and nonstructural proteins. The order and nomenclature of the cleavage products
are as follows: NH2-C-E1-E2-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH. C is viral nucleocap-
sid protein; El and E2 are virion envelope glycoprotein; NS2 through NS5B are putative
nonstructural proteins, at least some of which may be the functional equivalent of the
homologous proteins encoded by flaviviruses and pestiviruses. Studies on the processing of
structural proteins of HCV revealed that host signal peptidase localized in the lumen of en-
doplasomic reticulum is responsible for catalytic cleavages at the C/E1, E1/E2 and E2/NS2
junctions, which are reminiscent of the flaviviruses and pestiviruses. Predictive amino acid se-
quence data showed that N-termini of El, E2, and NS2 contain predicted signalase cleavage
sites and C-termini of C, El and E2 contain hydrophobic regions that are essential prere-
quisite for signalase cleavages.
A Zn2+-dependent metalloprotease comprising NS2 and the N-terminal one-third of the
NS3 is responsible for the autocatalytic cleavage at the NS2/3 junction (Grakoui et al, 1993c;
Hijikata et al, 1993a). But the proteolytic cleavage at the NS3/4A, NS4A/4B, NS4B/5A and
NS5A/5B junctions is catalyzed by serine protease, encoded by N-terminal one-third of the
NS3 gene (Grakoui et al, 1993a; Hijikata et al, 1993b; Tomei et al, 1993). For its efficient
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function as protease, NS3 needs NS4A as a co-factor. NS4A is required for the cleavage of
NS3/NS4A and NS4B/NS5A sites and enhances cleavage at the NS5A/5B site
(Bartenschlager et at., 1993; Failla et al, 1994). Cleavages at these sites occur either in cis or
in trans. Cleavage at the NS2/3 and NS3/4 sites normally occur in as, whereas at the other
sites normally occur in trans (Grakoui et al, 1993b; Tomei et al., 1993; Bartenschlager et al,
1995).
Properties of viral proteins
Separate gene regions are identified on the HCV genome from the 5' to the 3' end.











5'UTR |~ ~]- 1 3.UTR
structural | Nonstructural |
^^Y/vvvvv^/ ** *
Core Envelope NS2 NS3 NS4 NS5
^^#
/// x/^/^/x/N^ iwvj\ywvj lyw^^v
E1 E2 p-*,.,.,.,... NS5A NS5B
NS4A NS4B
Cleaved by :
# signalase, endoplasomic lumen
* viral coded enzyme (NS3 protease)
** viral coded enzyme (NS2-3 protease)
*
Fig. 1. Schematic presentation of a HCV particle, its genomic organization
and processing events of polyprotein.
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Structural proteins
The Core protein The core protein (C), molecular weight 22 kDa (p22), is located in
the ammoterminal region of polyprotein and is followed by the envelope and nonstructural
proteins. The first 190 amino acids of the N-terminal end of the polyprotein are identified as
core protein (Hijikata et al, 1991a). The C-protein contains high amount of basic amino acids,
arginine and lysine residues, (about 20%) like the nucleocapsid protein of flaviviruses and
pestiviruses, and many proline residues (about 12%) (Houghton et al, 1991; Choo et al,
1991a). It lacks N-glycosylation sites. The C-terminal domain contains 20 highly hydrophobic
amino acids and believed to act as a signal sequence which is recognized by a cellular
signalase, thereby cleaving the C-protein from the precursor polyprotein (Hijikata et al,
1991a; Kumar et al, 1992), P22 has an RNA binding capacity and can specifically bind to the
genomic RNA for the formation of nucleocapsid particles (Takahashi et al , 1992; Santolini et
al, 1994), P22 also contains several highly immunoreactive linear epitopes and can be used
for detection of early antibodies in most of the patients (Katayama et al, 1992; Okamoto et
al, 1992d; Isida et al, 1993).
The envelope proteins, El and E2 Two viral envelope glycoproteins, El and E2,
have been identified by cell-free translation and transient expression systems. The exact
cleavage site between C and El proteins catalyzed by the cellular signalase is considered to
be between Alal91 and Tyrl92 which occurs in the lumen of the endoplasomic reticulum (Hi-
jikata et al, 1991a). The El is a glycoprotein of approximately 35 kDa (p35) and contains 5
or 6 potential N-glycosylation sites that has been demonstrated by expressing the protein in
cell-free translation system, by N-glyconase treatment and by in vivo labeling using
glucosamine (Hijikata et al, 1991a; Matsuura et al, 1992). This region is equivalent to the E
region of flavi- or pestivirus but it is much shorter and there is no significant sequence
homology with them. The C-terminal of El glycoprotein contains a stretch of hydrophobic
amino acids (residues 348-370), which could act as a membrane anchor. El protein is syn-
thesized during the course of HCV infection (Matsuura et al, 1992; Kohara et al, 1992).
However, the antibody to the gp35 does not seem to be directly associated with the
neutralization of the virion.
The second envelope glycoprotein E2, molecular weight 70 kDa (p70), is coded by the
E2 region of the genome. The precise location of cleavage was determined at Gly383/His384
for E1/E2 (Hijikata et al, 1991a). The E2 protein is highly glycosylated and contains 9 or ll
potential N-linked glycosylation sites which have been identified by in vitro expression
system and by direct labeling of the expressed protein with 3H glucosamine (Hijikata et al,
1991a; Spaete et al, 1992). The N-terminus of E2 protein starts with residue His384 and its
C-terminus ends with amino acid residue Asn755 (Hijikata et al, 1991a). A conserved
repeated amino acid sequence motif has been identified between residues 471-511, and con-
tains 6 cystiene residues, indicating the possible complex secondary or tertiary structure of
the E2 glycoproteins.
When full-length E2 region was expressed in various animal cells by several expression
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systems, the expressed protein was membrane associated and was not secreted into the
medium. Presumably this was caused by the presence of a single membrane anchor at the C-
terminal, since C-terminal truncated E2 is rapidly secreted (Spaete et at., 1992). The N-ter-
minus of E2 is located at the outside of the virion and would allow surveillance by the im-
munesystem. However, baculovirus expression system showed that E2 protein could be effi-
ciently secreted in to the medium (Matsuura and Miyamura 1993). Moreover, the secreted
E2 protein was suggested to form a heterodimer with El protein that is co-immuno-
precipitable with E2 (Grakoui et al, 1993b; Ralston et al.t 1993). Conflicting results have
been reported regarding the interaction between El and E2 proteins. Ralston et al (1993) and
Matsuura et al. (1994) reported that El and E2 proteins are associated with each other in
their N-terminal regions by disulfide bonds, whereas Grakoui et al (1993b) reported that they
are linked by noncovalent interaction. Recent studies have suggested that El and E2
glycoproteins can also be bound with NS2 and NS3 proteins, whereas association of E2 and
NS4B was also reported (Grakoui et al, 1993b; Selby et al, 1994; Dubuission et al, 1994).
Such complex processing of HCV encoded proteins and protein: protein interaction suggested
their possible involvement in the morphogenesis of HCV particle.
The E2 glycoprotein corresponds to the NS1 glycoprotein of the flavivirus and the ma-
jor envelope protein gp53/gp55 (E2) of the pestivirus (Collet et al, 1988b; Spaepe et al,
1992). Both NS1 protein of flavivirus and E2 protein of pestivirus have been shown to
develop protective immunity in the immunized animals (Schlesinger et al, 1985; Hulst et al,
1993). Therefore, the mature form of E2 protein may have an important role in the infection
of HCV. However, the direct evidence suggesting the involvement of anti-E2 antibody for the
protection of HCV has not yet been obtained. Recently, Choo et al (1994) reported that
heterodimer complex of El and E2 proteins which were purified from the HeLa cells in-
fected with recombinant vaccinia viruses induced protective immunity in chimpanzees. Thus,
the result indicates that not only linear epitopes of the envelope proteins but also conforma-
tion-dependent epitopes on the complex of El and E2 proteins might be important for induc-
tion of protective immunity against HCV infection. Since flavivirus E protein contains a
number of biologically important epitopes including hemagglutination, neutralization and cell
attachment, the possibility that such reactive epitopes may exist in the E proteins of HCV
still remain to be determined.
There are two hypervariable regions (HVR1 and HVR2, Fig. 2) identified in gp70 of
HCV (Hijikata et al, 1991b; Weiner et al, 1991; Kato et al, 1992). One of them (HVR1) is
the region from the N-terminus of gp70 to amino acid residue number 27 and the another
(HVR2) is the region from amino acid 90 to 97 from the N-terminus. HVR1 lacks a conserv-
ed secondary structure and resembles the V3 loop of human immunodeficiency virus 1 gp!20
(Weiner et al, 1992). HVR1 contains a B-cell epitope and induces anti-HVRl antibody (Kato
et al , 1993). Amino acid substitution in the HVR1 could escape recognition by preexisting an-
ti-HVRl antibodies leading to escaped mutants that might play an important role for
establishing and maintenance of persistent infection by HCV (Kato et al, 1994).
The variability of gp70 may have significant implications for the development of a pro-
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tective immune response and is important in vaccine strategies. However, it would be dif-
ficult to develop an effective vaccine to control HCV infection if the HVRs contain neutraliz-
ing epitope(s).
HVR 1 HVR2
376 385 395 405 415 466 475 485
HCV-N LLFAGVDGST WTGGVQGRT TSVFTSLFSP GASQRVQLIN DQGWGPITY N NSGNSDQKP
HCV-1 AE H SAH VGV LA KN S A GSGP R
HCV-BK D H AAK NRLVMAS P KI AESR R
HCV-J H H RVASS QSLVWLQ P KI V A H DMPES R
HCV-JT V YT SAH QSV FTG PA I --A TEPRDL R
HCV-T I S TVA HSLA TQ KI TEADIQ R
HC-J6 A AQ HTV STAHNARTLGM L RKI RV ALQEDVTPEMR
HC-J8 V AT YSSQEA VAGAG TT KNLY - RI TLEETVTDGMR
Fig. 2. Variation in amino acid sequence of the hypervariable regions (HVR1 and HVR2)
of the E2 protein of 8 HCV isolates. HVR1 (amino acid 384-411) and HVR2
(amino acid 475-480) are indecated (data reproduced from Zheng, 1994).
Nonstructural proteins
The NS2 protein The nonstructural proteins appear to start with the NS2 region en-
coding a hydrophobic protein of about 23 kDa whose function is unknown. The biological
function of the gene product of the equivalent region of the flavivirus and pestivirus is also
unknown.However, in flavivirus NS2B acts as a co-factor for NS3 protease for the cleavage
of downstream sites of NS3 protein (Chambers et aL, 1991; Falgout et al, 1991; Arias et al,
1993; Lin et al, 1993). But in HCV, NS2 in conjunction with NS3 protein acts as a viral
metalloprotease, encompassing the NS2 region and the N-terminal portion of the NS3, which
is required for the autoproteolytic cleavage at the NS2/3 site (Hijikata et al, 1993a; Grakoui
et al, 1993c). The region between amino acid residues 898-1233 was shown to be essential
for the detection of this second viral Zn+2 requiring metalloprotease.
The NS3 protein The nonstructural protein NS3, molecular weight 70 kDa, shows
limited amino acid homology with corresponding flavivirus and pestivirus protein. NS3 pro-
tein contains two distinct functional domains essential for virus replication. The N-terminal
one third of the NS3 contains a protease domain similar to that found in flavi- and
pestiviruses (Bartenschager et al, 1993, 1995; Grakoui et al, 1993a; Tomei et al, 1993; Pizzi
et al , 1994). Amino acid sequence analysis of the putative NS3 protein shows conservation of
residues His-1083, Asp-1107 and Ser-1165 among all HCV strains so far sequenced. The
nature and position of these residues resemble to the catalytic triad of chymotrypsin-like
serine protease. If the Ser-1165 in the proposed catalytic site is replaced with another amino
acid, the proteolytic activity of the NS3 protein is abolished. All four cleavages that occur at
C-terminal of the protease domain (NS3/4A, 4A/4B, 4B/5A and 5A/5B) were abolished by
modification of His 1083 and Ser 1165. These cleavage sites shows several commonfeatures,
which probably determine the substrate specificity of the NS3 protease. NS3 acts in cis on its
ownN-and C-terminals but the remaining three C-terminal sites can only be processed by
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NS3 in trans.
Predicted amino acid sequence analysis and experimental data have also revealed that
the C-terminal of NS3 protein contains a nucleoside triphosphate binding helicase domain
(Miller and Purcell, 1990; Suzich et al, 1993) that are presumably involved in the unwinding
of the binding dsRNA replicative intermediate, which is necessary for genome replication,
The NS4 proteins The NS4 protein, which is hydrophobic and contains highly im-
munogenic epitopes, is processed into NS4A (MW 4 kDA) and NS4B (MW 27 kDa), whose
exact functions are still unknown. Some experimental data have shown that NS4A binds with
NS3 and make a heterodimer complex which in turn binds to the NS4B, NS5A and NS5B to
form a complex structure and thereby helps virus replication (Hijikata et al, 1993b; Tanji et
al, 1995). In vitro transcription and translation of the HCV polyprotein revealed that NS4A
helps to anchor NS3 protein to the surface of the microsomal membraneby their mutual
association. Recent report showed that NS4A is necessary for cleavage at the NS3/4A and
NS4B/5A sites and enhances the efficiency of the cleavages at the NS5A/5B and NS4A/4B
sites (Bartenschlager et al, 1994; Failla et al, 1994, 1995). Very recently, Tanji et al. (1995)
reported using a transient protein expression system that NS4A helps in stabilization and
localization of the NS3 protein. In case of flaviviruses, NS2B is required as a co-factor to
facilitate efficient proteolytic processing of the nonstructural region of the viral polyprotein
by NS3. Despite their different topological arrangement on their respective genome, NS4 of
HCV and NS2 of flaviviruses are believed to have some commonfunctional properties, that
is, both act as co-factor of NS3 protease, can function either in as or in trans, and can
liberate from their respective catalytic domains by an intramolecular cleavage.
The NS5 proteins The nonstructural protein NS5 is processed into NS5A (MW 56
kDa) and 5B (66 kDa). The NS5A protein contains important B-cell epitopes whose function
is still unknown (DeLeys et al, 1993). NS5B contains a sequence motif, Gly-Asp-Asp (residue
2737- 2739), which is characteristic for RNA-dependent RNA polymerases of positive strand-
ed RNA viruses (Miller and Purcell, 1990). Therefore, NS5B is considered to encode viral
replicase essential for virus replication.
The noncoding regions
The 5' UTR According to sequence data of Han et al. (1991), the 5' UTR is 341
nucleotide in length but many shorter sequences have been reported. Moreover, it has been
suggested that HCV genome can exist as a truncated RNA molecules at vivo (Han et al,
1991), implying difficulty to determine the precise terminus of the native RNA genome. The
5' UTR is highly conserved amongHCV isolates, about 93% nucleotide sequence identity
between groups and about 98% nucleotides identity within group (Matsuura and Miyamura,
1993). The 5' UTR of HCV is very much similar to pestivirus bovine viral diarrhoeal virus
(BVDV) and hog cholera virus (Houghton et al, 1991). The HCV 5' UTR is composed of a
relatively long leader and contains five small open reading frames (ORF) that are comparable
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to picornaviral 5' UTR which is unusually long, ranging from 610-1200 nucleotides depen-
ding on the virus isolates, and contains many silent AUG codons. But it is still unknown
whether these ORFs in HCV genome are actually translated and what are the functions of
the gene products (Kitamura et al, 1981; Yoo et al, 1992). The secondary structure analysis
of the 5' UTR of HCV has indicated the presence of a large conserved stem-loop structure
in the proximal part of the 5' UTR, which serves as a putative internal ribosomal entry site
(IRES). Other studies using the mono-and dicistronic RNA constructs suggested the ex-
istence of an IRES in the HCV 5' UTR (Wang et al, 1993). From the genetic organization
of the 5' UTR, it has been postulated that the process of translation initiation of the HCV
genomemaybe similar to that of picornaviruses. The mechanism of translation initiation us-
ed by picornaviruses involves the binding of ribosomes to a complex secondary/tertiary struc-
ture, which is called as IRES, within the 5' UTR of the viral genome. The IRES mechanism
allows cap independent translation of the genome (Pelletier and Sonenberg, 1988). Thus,
HCV polyprotein translation seems to be cap independent and initiates at an IRES within the
5' UTR, proximal to the initiator AUG codon of the polyprotein (Tsukiyama-Kohara et al,
1992; Wang et al, 1993). The initiation of translation seems to be inhibited by the presence
of a 5' terminal 27 nucleotides sequence capable of forming a stable hairpin structure (Han
et al, 1991), which is highly conserved in picornavirus.
The contradictory report has also been published to explain the ribosome scanning
mechanism for translation initiation of HCV polyprotein (Yoo et al, 1992). Ribosome scann-
ing mechanism for protein translation needs a cap structure at the 5' end of the genomic
RNA which binds to the ribosome with the help of cellular initiation factor elF-4F, and initia-
tion occurs at the AUG codon nearest to the 5' end. Unlike flaviviruses, HCV lacks a cap
structure at the 5' end of the RAN genome.
The 3' UTR The reported 3' UTR of HCV shows significant variation both in length
(27 to 66 nucleotides) and in sequence (26 to 40% identity between groups). It is reported
that HCV contains an homopolimer tail of 10 to 100 residues at the 3' UTR, which is iden-
tified as a poly A tail for some isolates (Choo et al, 1991a, b; Han et al, 1991), whereas a po-
ly U tail is present for other isolates (Kato et al, 1990; Takamizawa et al, 1991; Chen et al,
1992; Okamoto et al, 1992b; Tanaka et al, 1992). More investigations are still necessary to
clarify this issue whether 3' terminus contains poly A or poly U tail. Another remaining
issue need to be solved is whether the reported 3' -terminal sequences are completed or not.
The 3' terminus is very important for plus stranded RNA viruses for RNA replication
because it provides a entry site for RNA polymerase to copy the minus strand, indicating
that this region might be important for the RNA replication of HCV.
Genotyping of HCV
Since the isolation of the first full-length CDNA of HCV by Chiron group, to date the
entire genome of at least 17 isolates are available and a numerous partial sequence of HCV
isolates have been reported throughout the world. The nucleotide sequence analysis of the 17
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isolates have revealed that they are identical in only 68.1 to 91.8% indicating the existence of
more than one type of HCV in nature. It is believed that this degree of sequence variability
is sufficient to alter the antigenic and biological properties of the virus significantly. Data
from recent studies have shown that samples reactive with the second generation commercial
test kit but non-reactive or Intermediate' with the first generation test, suggest that these
are presumably new types or variants of HCV (Cha et al, 1992). Supporting this hypothesis
is the recent discovery of HCV variants that differ markedly in nucleotide sequence from the
original American and Japanese types (Enomoto et al., 1990; Nakao et al, 1991; Okamoto et
al, 1991). In addition, there is some evidence for variation in the course of infection
associated with different HCV viriants and in response to treatment with interferon (Kanai et
al, 1992; Yoshioka et al, 1992). Altogether these evidences stress the importance of HCV
genotyping.
Since the nucleotide sequence variation is distributed throughout the viral genome, com-
parison of full-length genome sequences is the best way to identify the HCV isolates, but
practically it is quite impossible due to many limitations. Some part of the genome especially
regions encoding the putative envelope proteins (El and E2) are most variable, whereas the
5' UTR is most conserved. For genotyping of HCV, 5' UTR and some less variable part, for
example C, El, NS2, NS4, or NS5 can be used for this purpose.
Based on full-sequence information and nucleotide sequence similarity, 17 HCV isolates
have been classified into 3 groups or types and 6 subgroups or subtypes (Sakamoto et al,
1994; Zheng, 1994). A proposed classification for these 17 isolates is shown in the Table 1.
In Japan, HCV II/Ib is the main subtype followed by subtypes III/2a and IV/2b. In
Japan, about 70% of patients with chronic hepatitis were infected by HCV II/Ib, while 20%
of them by III/2b and 10% of them by IV/2b, respectively. Mixed infection with ll+III,
ll+IV and I+V account only a small fraction of the HCV infected patients (see Okamoto et
al, 1992c).
Several classification systems have been proposed based on nucleotide sequence infor-
mation of specific region of the HCV genome and found that there are some advantages
Table. 1 Classification of 17 HCV strains based on entire nucleotide sequence information of
their genome into group, subgroup and isolate as proposed by Sakamoto et al (1994)
and Zheng (1994).
Group Subgroup I solate s D istri buti on
|/la HCV-1, HCV-H, HC-J1 USA, Japan
Group 1 J^ HC-G9 Indonesia
ll/lb HC-J4/83, HC-J4/91, HCV-J, HC-C2, HCV-JT, Japan, China, Taiwan
HCV-JT', HCV-BK, HCV-T, HCV-JK1, HCV-N
Group 2 -^ HC-J6 Tapan
l V/2b HC-J8 Japan
Group 3 | v/3a | NZL1 New Zealand
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and disadvantages associated with the system regarding the establishment of new types or
subtypes (Chan et al, 1992; Stuyver et al., 1993; Simmonds et at., 1993a). Recently, Sim-
monds et al (1993b) proposed a new classification system based on sequence alignments of
NS5 of a large number of HCV sequences derived from a variety of geographical regions.
They revealed that the proposed classification is more appropriated and new groups (types)
or subgroups (subtypes) can easily be fitted into the new system.
Infection rate in Japan
The prevalences of anti-HCV measured by the first and the second generation assays
have been reported in many countries in the world. All these surveys showed that the carrier
rates were almost same in Europe and North America which is about 1%. The rate is slightly
higher in Middle East and Asia about 1-3%, and in Africa and Egypt, the rate may exceed
these ranges (see Nishioka, 1994).
The prevalence of HCV infection among Japanese blood donor has been documented in
Japan using the first and the second generation anti-HCV assays, which indicated that HCV
infection rate is slightly higher in the western part and high rates exist among the older peo-
ple over 50. The percentages of anti-HCV positivities for each age group were 0.36% (16-20
years), 0.69% (21-30 years), 1.14% (31-40 years), 1.74% (41-50 years) and 2.78% (51-64
years). Concurrently, when 1,224 presumably healthy school children (5-15 years) were
tested, none of them were anti-HCV positive.
It has been demonstrated that in Japan, almost 90% of all main liver diseases, i.e.
chronic hepatitis, liver cirrhosis and hepatocellular carcinoma are associated with HBV or
HCV (see Esumi and Shikata, 1994). In Japan, 70% chronic hepatitis cases are due to HCV
infection, whereas only 30% due to HBV. In liver cirrhosis cases, about 65-70% were
associated with HCV infection, less than 20% with HBV and less than 10% due to alcohol
consumption. But in case of hepatocellular carcinoma, almost 80% were due to HCV infec-
tion, whereas less than 20% cases were due to HBV. So HCV alone is responsible for about
65 to 80% of liver diseases in Japan.
In the United States, HCV is considered as a major cause of both chronic liver diseases
and persistent viremia which account for an average of 21% of acute viral hepatitis cases.
The carrier rates of HCV in Japan and the United States are almost similar but the incidence
of hepatocellular carcinoma in these two countries are not similar. It is speculated that this
difference is either by different virus subtypes (subgroups) or different routes of infection. In
Japan, most of the infections are due to HCV subtype II, whereas subtype I is most
prevalent in the United States. These two virus types considerably vary both in the
nucleotide (14-16%) and amino acid (ll-22%) sequences (Choo et al, 1989; Takamizawa et
al, 1990; Kato et al, 1990). In Japan, the major route of HCV infection is considered to be
blood transfusion. In the United States, HCV infection is much more predominant among
drug abusers. Since the development of liver cirrhosis and hepatocellular carcinoma needs 20
to 30 years after HCV infection, these people die before the appearance of hepatocellular car-
cinoma. More investigations are still needed to identify the actual causes associated with the





Transfusion of blood products from the HCV infected donors has been documented as
a major route of HCV infection throughout the world. HCV infection at high rate was also
à"eported among hemophiliac patients (Oguchi et at., 1990; Watson et al., 1992; Laurian et al,
1992). Moreover, several cases of HCV infection were also reported among intravenous im-
munoglobulin recipients in the United States, Sweden, Spain and England (Williams, 1988;
Nishioka, 1994). Transmission of HCV infection from infected person to health care workers
through needle stick injuries have also been reported in Japan (Kiyosawa et al, 1991; Mitsui
et al, 1992). The intravenous drug abusers are the high risk group for HCV infection. The
HCV infection rates among intravenous drug users range from 56 to 80% (Iwamura et al,
1992; IARC, 1994).
2) Non-parenteral
Perinatal transmission of HCV has been documented in several studies and confirmed
that vertical transmission of HCV can take place (Ohto et al, 1994). Controversial results
have been reported for sexual transmission of HCV (Melbye et al, 1990; Gordon et al, 1992;
Bresters et al, 1993; Kao et al, 1993; Skidmore et al, 1994). Careful epidemiological studies
are required to resolve this issue. Intrafamilial transmission of HCV was also reported
(Kamitukasa et al, 1987).
Diagnosis of HCV infection
Two highly sensitive and specific virological methods are now available to diagnose
HCV infection: 1) detection of circulating antibodies by the second generation ELISA assay
and, 2) detection of HCV genome sequences from infectious materials by the reverse
transcription-polymerase chain reaction (RT-PCR). The first one is referred as serodiagnosis
and the second one as genodiagnosis. The routine method for detection of HCV infection is
mainly performed on the basis of these two assays.
Serodiagnosis
The first generation assay for the detection of anti-HCV became available in 1989 utiliz-
ing a recombinant yeast expressed antigen, C100-3, which contained antigenic epitopes
located in the NS3-NS4 region (Kuo et al, 1989). Anti-C100-3 was used for diagnosis of HCV
from patient serum and screening donor blood and prevented 60-80% post transfusion non
A non B hepatitis in Japan (Watanabe et al, 1993; Japanese Red Cross NANB Hepatitis
Research Group, 1991).
In the improved second generation anti-HCV ELISA assay, recombinant core antigen
was added to the previously used C100-3 antigen. This assay was found to be more sensitive
than the first generation ELISA. In addition to the ELISA, agglutination test using gelatin
particles or fixed erythrocytes coated with the second generation antigens have been used to
measure anti-HCV antibodies. The second generation assay systems showed excellent perfor-
mancein detecting anti-HCV in donor blood. In Japan, almost 99% donor blood can nowbe
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screened by the second generation assay systems (Esumi and Shikata, 1994). Thus, in Japan
post transfusion HCV is almost under control.
In the third generation assay, NS5 antigen has been added to the second generation
test to make it more sensitive. These anti-HCV antibody assay systems detect mainly IgG
type antibodies. Recently, attempts have been made to detect IgM type antibodies from
clinical specimens and these assays were found to be quite useful in early diagnosis of HCV
infection (Brillanti et aL, 1992; Clemens et aL, 1992).
Genodiagnosis
Since the isolation of a CDNA clone by Chiron group, diagnoses on HCV infections
have been conducted by the detection of viral RNA by RT-PCR. HCV RNA is extracted
from serum samples and CDNAis synthesized by reverse transcriptase and amplified by the
PCR using HCV-specific primers. Primer selection is prerequisite to obtain accurate results.
Generally primers are selected from the highly conserved region of the HCV genome,
preferably from 5' UTR and C-protein region. Other regions such as NS5 can also be used
for this purpose. The nested RT-PCR has been performed in order to increase the specificity
and sensitivity of the PCR (Garson et aL, 1990; Okamoto et aL, 1990, 1992c). Competitive
RT-PCR has also been used for the quantative detection of HCV-RNA from infectious
materials, providing a very useful quantative method (Kaneko et aL, 1992; Hagiwara et alf.
1993).
Markers useful for detecting acute hepatitis C
Detection of IgG antibodies is not a useful marker in the early diagnosis of acute
hepatitis C. Since the second generation ELISA assay can only detect IgG type antibodies,
half of the HCV positive patients become negative to this test within one month after the
onset of the disease (Hino, 1994). But during this time, all HCV patients show RNA levels
which can easily be detected by RT-PCR. So the best marker for diagnosis of acute HCV in-
fection is the detection of HCV-RNA.Transient infection can also be diagnosed by detecting
HCV RNA. In case of transient infection, acute phase is very important, because RNA level
from patient serum decrease to undetectable level after three months of onset. So diagnosis
becomes impossible if the acute phase is missed.
Quantitative assay for both second generation anti-HCV IgG and IgM can be applied to
differentiate acute and chronic hepatitis C. At the early stage of infection, most of the pa-
tients show detectable level of serum IgM and undetectable level of IgG. After 3 month of
onset, anti-HCV IgG can be detected at high rates, while IgM level may be absent or present
at low level. So in the early stage of acute hepatitis C, IgM is positive while in chronic cases,
IgG antibodies are always present in high levels.
Serum alanine amino transferase (ALT) levels
Serum ALT is not always a useful indication to detect hepatitis C virus infection. It
has been found that some patients with HCV infection have normal ALT level. In such case,
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determination of past and current infection is obligatory which might be difficult by determin-
ing the HCV RNA and anti-HCV antibodies. So in this case, quantative assay of HCV RNA,
anti-HCV IgG and anti-HCV C-protein are very useful to differentiate past and current infec-
tion.,
Liver biopsy is also an effective diagnosis to detect the HCV infection because healthy
carrier is hardly found.
Persistent infection with HCV
The mechanisms by which acute HCV infection develops into persistent infection in the
samepatient have not been clearly understood. Most plausible explanation for chronicity was
given by the genomic structure of the HCV. It has been noted that HCV genome undergoes
frequent mutations during natural course of chronic infection. The overall mutation rate of
the entire HCV genome in a chronically infected chimpanzee has been estimated between 0.9
and 1.92 x 10~3 base substitution per site per year (Ogata et al., 1991; Okarnoto et al, 1992a;
Abe et al., 1992).
Recent molecular biological studies of HCV from chronically infected patients indicate
that most of the individuals contain a large variety of related HCV sequences described as
'quasispecies' (Martell et al, 1992). Different HCV sequences from a single patient at dif-
ferent time intervals were also reported (Murakawa et al, 1992), indicating that some parts
of the HCV genome undergo selection pressure and able to escape from the immune-
surveillance system which might play a crucial role in the mechanism of persistent chronic in-
fection (Enomoto et al, 1993; Higashi et al, 1993; Kato et al, 1993; Sakamoto et al, 1994;
Kurosaki et al, 1994). To clarify the potential mechanism of chronic HCV infection with
acute hepatitis, the amino acid substitutions in the El, E2, and NS3 regions of HCV strains
have been investigated extensively in several studies (Ogata et al, 1991; Okamoto et al,
1992a, Kato et al, 1992). It has been reported that after the IFN treatment, the HCV RNA
in serum decreases significantly, but subsequently reappears. During this period, the amino
acid substitution rate in the HVR I of E2 increased significantly. Thus it is predicted that
the rapid amino acid substitution in the HVR I might be one of the mechanism of chronicity
in HCV infection.
Hypervariability and 'Quasispecies'
Comparison of the amino acid sequences of the envelope region, El and E2, of multiple
HCV isolates have identified two hypervariable regions (HVR, Fig. 2). HVR 1 near the N-ter-
minus of E2 consists of 27 amino acids and the HVR2 consists of 8 amino acids, position 90
to 97 from the N-terminus of E2 region (Hijikata et al, 1991b; Kato et al, 1992). The impor-
tance of HVR1 in the disease mechanism associated with HCV has been analyzed in a few
studies which indicated that HVR1 was directly associated with the development of chronic
infection. The alteration of amino acids in HVR1 occurs sequentially during the natural
course of chronic infection at a rate of 0.5 to 1.7 amino acids per month (Kato et al, 1992).
HVR1 was able to induce anti-HVRl which could only neutralize the homologous virus
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isolate and HCV with an amino acid substitution in its HVR1 could escape from recognition
by preexisting anti-HVRl antibodies, indicating the possible importance of the HVR1 in
chronic infection by HCV (Kato et at., 1993).
The appearance of amino acid substitution in HVR during chronic HCV infection has
been observed in many studies. These substitutions have been explained either by viral cod-
ed RNA-dependent RNA polymerase needed for genome replication or by selective immune
pressure on viral particles imposed by infected host. Errors may accumulate as mutation dur-
ing replication of viral genome by RNA-dependent RNA polymerase, due to lack of proof-
reading activity of this enzyme encoded by all RNA viruses. As a result, variant RNA
genomes evolve in vivo that form a quasispecies population which contain one or more
master sequence and a large spectrum of closely related variants (Holland et al, 1992).
Several closely related sequences have been isolated from a single HCV infected patient
(Murakawa et at., 1992). Of course in such case, the possibility of infection by more than one
virus strain cannot be ruled out. Since the HVR is thought to contain neutralizing epitopes,
selective immune pressure of the infected host may give rise to the mutation in the viral
genome which can escape from the host immunity.
Moreover, phylogenetic analysis have suggested that there are two different genetic
mechanisms underlying the change in HVR sequences, either by continuous accumulation of
mutations de novo and/or selective overgrowth of preexisting minor variants from the large
spectrum of quasispecies populations (Kurosaki et al , 1994).
Treatment of HCV infection
Until now, there is no known chemotherapeutic agents available for the treatment of
HCV infection. Despite unusual side effects , interferon (IFN) is the only drug which has
been used for the treatment of acute and chronic hepatitis C virus infection. IFN is believed
to induce 2' -5' oligo-adenylate synthetase which in turn inhibit the viral protein synthesis
and thereby inhibit the viral replication (McNair and Kerr, 1992). It has been reported that
most of the HCV patients effectively respond to the IFN and show normal ALT level and
negative HCV RNA within six months of treatment and remain normal at least six months
after completion of therapy (Shindo et al, 1991). However, subsequent to the withdrawing of
IFN treatment, HCV RNA and ALT reappear and become worse even than pretreatment
level and the disease turns into chronic state (Davis et al, 1990; Lindsay et al., 1990). The
reason of why all the patients do not respond equally to IFN treatment and why IFN cannot
clear the virus from the system are still unknown. The outcome of the IFN treatment ap-
pears to depend on 1) the condition of the liver histology, 2) the HCV-RNA level of the
serum and 3) the presence of HCV genotype.
Concluding remarks
The new information obtained about the structure and function of the HCV genes and
their proteins since the initial characterization of the HCV is really impressive. Due to the
lack of an in vitro replication system for HCV, investigation of the many biological functions
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such as mechanism of replication of the viral genome, host-virus interaction, morphogenesis
of virus particles, function of individual viral coded protein, immunology, viral inhibition
assays etc have been greatly impeded. Therefore the establishment of an in vitro propagation
system for HCV is imperative. The development of an effective chemotherapeutic agent is
obligatory which can be used to cure HCV infected patients. In this purpose, viral coded en-
zymes, such as protease, helicase, replicase etc could be attractive targets. Therefore, it is
necessary to obtain more information about the molecular biology and replicative strategy of
HCV. The role of cellular and humoral immune responses should be investigated extensively
in order to provide insight into the chronicity associated with HCV infection. The construc-
tion of infectious CDNA of HCV should provide useful approaches for studying molecular
biology and pathogenesis of HCV infection and help to prevent and control of HCV infection.
With the advent of the first and the second generation ELISA, most of the post-transfusion
non A non B hepatitis is now under control. So we greatly hope that HCV and HCV-
associated diseases can be controlled effectively in the near future.
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